These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 19898280

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ischemia is the critical determinant of revascularization benefit: an interventionalist's perspective of the COURAGE trial.
    Kereiakes DJ.
    Rev Cardiovasc Med; 2009; 10 Suppl 2():S45-52. PubMed ID: 19898281
    [Abstract] [Full Text] [Related]

  • 3. Impact of optimal medical therapy and percutaneous coronary intervention on patients with stable angina.
    Latib A, Chieffo A, Colombo A.
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):92-3. PubMed ID: 19065124
    [Abstract] [Full Text] [Related]

  • 4. One year perspective on COURAGE.
    Tommaso CL.
    Catheter Cardiovasc Interv; 2008 Sep 01; 72(3):426-429. PubMed ID: 18727125
    [Abstract] [Full Text] [Related]

  • 5. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
    Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA.
    JAMA; 2011 May 11; 305(18):1882-9. PubMed ID: 21558519
    [Abstract] [Full Text] [Related]

  • 6. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z, Jones P, Weintraub WS, Mancini GBJ, Sedlis S, Maron DJ, Teo K, Hartigan P, Kostuk W, Berman D, Boden WE, Spertus JA.
    Circ Cardiovasc Qual Outcomes; 2018 May 11; 11(5):e003971. PubMed ID: 29752388
    [Abstract] [Full Text] [Related]

  • 7. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS, COURAGE Trial Investigators.
    J Am Coll Cardiol; 2009 Sep 29; 54(14):1303-8. PubMed ID: 19778673
    [Abstract] [Full Text] [Related]

  • 8. Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.
    Soares A, Boden WE, Hueb W, Brooks MM, Vlachos HEA, O'Fee K, Hardi A, Brown DL.
    J Am Heart Assoc; 2021 Jan 19; 10(2):e019114. PubMed ID: 33442990
    [Abstract] [Full Text] [Related]

  • 9. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
    Mancini GBJ, Boden WE, Brooks MM, Vlachos H, Chaitman BR, Frye R, Bittner V, Hartigan PM, Dagenais GR.
    Atherosclerosis; 2018 Oct 19; 277():186-194. PubMed ID: 29861270
    [Abstract] [Full Text] [Related]

  • 10. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
    Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators and Coordinators.
    Circ Cardiovasc Qual Outcomes; 2013 Jul 19; 6(4):409-18. PubMed ID: 23838107
    [Abstract] [Full Text] [Related]

  • 11. Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).
    Sedlis SP, Jurkovitz CT, Hartigan PM, Kolm P, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, Boden WE, Weintraub WS, COURAGE Study Investigators.
    Am J Cardiol; 2013 Dec 01; 112(11):1703-8. PubMed ID: 24011740
    [Abstract] [Full Text] [Related]

  • 12. Re: One year perspective on COURAGE.
    Sedlis SP, Boden WE, Weintraub WS, Maron DS, O'Rourke RA, Berman DS, Mancini GB, COURAGE study Investigators.
    Catheter Cardiovasc Interv; 2009 Feb 15; 73(3):428. PubMed ID: 19133682
    [No Abstract] [Full Text] [Related]

  • 13. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
    Maron DJ, Spertus JA, Mancini GB, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE, COURAGE Trial Research Group.
    Am J Cardiol; 2009 Oct 15; 104(8):1055-62. PubMed ID: 19801024
    [Abstract] [Full Text] [Related]

  • 14. Clinical implications of the BARI 2D and COURAGE trials: overview.
    Brooks MM, Boden WE, Frye RL.
    Coron Artery Dis; 2010 Nov 15; 21(7):383-5. PubMed ID: 20664331
    [Abstract] [Full Text] [Related]

  • 15. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.
    Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S.
    Circ Cardiovasc Interv; 2012 Aug 01; 5(4):476-90. PubMed ID: 22872053
    [Abstract] [Full Text] [Related]

  • 16. Should percutaneous revascularization for stable coronary artery disease be performed sooner or later?
    Prasad A, Gersh BJ.
    JACC Cardiovasc Interv; 2008 Oct 01; 1(5):480-2. PubMed ID: 19463348
    [No Abstract] [Full Text] [Related]

  • 17. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.
    Acharjee S, Teo KK, Jacobs AK, Hartigan PM, Barn K, Gosselin G, Tanguay JF, Maron DJ, Kostuk WJ, Chaitman BR, Mancini GB, Spertus JA, Dada MR, Bates ER, Booth DC, Weintraub WS, O'Rourke RA, Boden WE, COURAGE Trial Research Group.
    Am Heart J; 2016 Mar 01; 173():108-17. PubMed ID: 26920603
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study.
    Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N, Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H, Japanese Stable Angina Pectoris Study Investigators.
    JACC Cardiovasc Interv; 2008 Oct 01; 1(5):469-79. PubMed ID: 19463347
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.